King licenses Aventis products
Executive Summary
King Pharmaceuticals (acquires and sells branded pharmaceuticals) licensed exclusive US (including Puerto Rico) and Canadian rights from Aventis to two marketed asthma products, Intal (cromolyn sodium) and Tilade (nedocromil sodium), and exclusive global rights outside of Japan to Synercid (dalfopristin, quinupristin), for €189.9mm ($199mm) in cash.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice